



# Boost your career

Creating future leaders in biomedical development

Paul Janssen Futurelab is an international learning initiative. Our online and on-campus course targets post-graduate entrepreneurial biomedical professionals with experience working in academia, start-ups, industry, and regulatory authorities.

www.pauljanssenfuturelab.eu




Average rating of our courses

## **Market Approval**

Five-week online course with online exam

Market approval is a crucial step in the development of a new biomedical product. In this learning-by-doing course, you will learn how to design a regulatory strategy to navigate the approval process. Real-world case studies, including the development of a gene therapy product and a fictitious mRNA vaccine, will be presented in order to familiarize yourself with regulatory strategic issues. Each week starts with an episode of our educational documentary entitled "The Rise, Fall and Return of Thalidomide".

Next starting date for this course October 25th, 2021



**Murray 'Mac' Lumpkin** Former director of the anti-infective drug division; deputy director, CDER; deputy commissioner, FDA

Onno van de Stolpe Former CEO Galapagos Spiros Vamvakas Head of Scientific Advice European Medicines Agency

And many more

# **Full program**

#### Week 1 - Benefit / Risk balance

A brief introduction to the history and current regulatory systems for receiving market approval of medicinal products, medical devices, and medical nutrition products. Futurelab talk by **Eline Bunnik** (Assistant Professor, Erasmus Medical Center) – "Ethics and autonomy in drug regulation".

#### **Topics**

- Clinical trials and informed consent
- Compassionate use and the "Right to Try"
- Benefit / Risk balance
- Regulatory assessment criteria

#### **Practical cases**

- Melatonin, a medical product with many faces
- Bedaquiline for MDR tuberculosis, including the FDA advisory committee meeting

T introductory videocall

#### Week 2 - Stakeholders in market approval

Interview with **Julia Bernholtz** (COO, AM Pharma) – Target Product Profile. Futurelab talk by **Henk Schuring** (Chief Regulatory and Commercialization Officer, Prilenia) – "Developing medicinal products for orphan diseases".

#### **Topics**

- Claims, evidence and reasoning
- Label claim: off-label use
- Target Product Profile (TPP)
- The project team

#### **Practical cases**

- TPP: a new indication for Sirturo<sup>®</sup> (bedaquiline)
- Genzyme's Cerdelga® (eliglustat)
- uniQure's Glybera® (alipogene tiparvovec)

### Week 3 - Regulatory intelligence

Futurelab talk by **Bernd van der Meulen** (Professor of EU Food Law, University of Copenhagen) - "Phood: the interface between food and medicine".

#### **Topics**

- Product classification
- Regulatory guidelines
- The Market Approval Navigator tool
- Common Technical Document (CTD)
- Investigational Medicinal Product Dossier (IMPD)
- Regulatory dossier assessment

#### **Practical cases**

- Locate and read regulatory guidelines
- Use the Market Approval Navigator tool
- Gap analysis of a peptide product IMPD



#### Week 4 - Authority consultation

Interview with **Spiros Vamvakas** (Head of Scientific Advice, EMA) – "Best practices in authority consultation". Interview with **Onno van de Stolpe** (former CEO, Galapagos) – "Market approval of Jyseleca<sup>®</sup> (filgotinib)".

#### **Topics**

- Preparation for authority consultation
- Pediatric development
- The briefing package
- Running a meeting with authorities
- Negotiation/communication with authorities

#### **Practical cases**

- Prepare authority consultation for a medicinal product with companion diagnostics in Alzheimer's disease
- Exercise to run an authority meeting for a product used for pediatrics
- Genentech's communication with the FDA in the process for market approval of Activase<sup>®</sup> (alteplase)

#### Week 5 - The product's life-long positive Benefit / Risk balance

Futurelab talk by **Sjaak Bot** (former head of Regulatory Affairs at Janssen) - "Regulatory life cycle management".

#### Topics

- Product life cycle
- Pharmacovigilance and risk management
- Communicating the benefit/risk balance to the general public
- Accelerating market approval
- Tolerability of risk
- Public assessment reports


#### **Practical cases**


- Vioxx and killing a product's development in time
- University of Oxford/AstraZeneca's COVID-19 vaccine Vaxzevria<sup>®</sup> (ChAdOx1 nCoV-19)
- Biogen's Alzheimer's drug Alduhelm<sup>®</sup> (aducanumab)
- Development of a new mRNA-based vaccine

#### T 🔓 Final videocall

#### **Final exam**

You can schedule your online exam after completing week 5. Upon passing the exam, you will receive a certificate.





This all-new online course will start in fall 2021. Space is limited, so be sure to sign-up on time.

#### Market Approval Online - October, 2021

Course length	5 weeks	Videocall 1	Oct. 28, 2021 18:30 to 19:30 (CET)
Study load	5-7 hours a week		
		Videocall 2	Nov. 18, 2021
Online course starts	Oct. 25, 2021		18:30 to 19:30 (CET)
Online exam period	Dec. 6-12, 2021	Videocall 3	Dec. 2, 2021
			18:30 to 19:30 (CET)





Visit our website for a free online demo

**film** Paul Janssen Futurelab's documentary on the story of thalidomide.


 Real-life cases, involving AstraZeneca's Vaxzevria<sup>®</sup>, Janssen Therapeutic's Sirturo<sup>®</sup>, Genzyme's Cerdelga<sup>®</sup>, uniQure's Glybera<sup>®</sup>, Genetech's Activase<sup>®</sup>, Biogen's Alduhelm<sup>®</sup>, and fictitious cases with exercise and assignments.

tool Our Market Approval Navigator can help you locate relevant guidelines from the EMA, FDA, and ICH.

**class** Follow the course with a group. Meet fellow participants via chat boxes and videocalls, discuss assignments, and exchange insights regarding the topics of this course.



Our participants come from all over the world and represent various disciplines, bringing their unique expertise, learning goals, and perspectives.







www.pauljanssenfuturelab.eu